Clarity Pharmaceuticals Reports Significant Clinical Trial Milestones for Prostate Cancer Treatment

Clarity Pharmaceuticals announced major progress in its late-stage SAR-bisPSMA clinical trials for prostate cancer, including the completion of recruitment for the AMPLIFY Phase III imaging trial. Data for 67Cu-SAR-bisPSMA in metastatic prostate cancer showed a 63% PSA50 response and a 31% complete/undetectable disease rate, with a favorable safety profile.